Schonfeld Strategic Advisors LLC Increases Stock Position in Evolus, Inc. (NASDAQ:EOLS)

Schonfeld Strategic Advisors LLC boosted its stake in Evolus, Inc. (NASDAQ:EOLS) by 62.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 34,700 shares of the company’s stock after acquiring an additional 13,363 shares during the period. Schonfeld Strategic Advisors LLC owned about 0.05% of Evolus worth $383,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Nantahala Capital Management LLC raised its holdings in shares of Evolus by 10.8% in the fourth quarter. Nantahala Capital Management LLC now owns 3,130,149 shares of the company’s stock valued at $34,557,000 after buying an additional 305,300 shares during the last quarter. Northern Trust Corp raised its holdings in shares of Evolus by 9.3% in the fourth quarter. Northern Trust Corp now owns 531,167 shares of the company’s stock valued at $5,864,000 after buying an additional 45,384 shares during the last quarter. Tri Locum Partners LP purchased a new stake in shares of Evolus in the fourth quarter valued at about $8,198,000. Boothbay Fund Management LLC raised its holdings in shares of Evolus by 30.9% in the fourth quarter. Boothbay Fund Management LLC now owns 1,287,767 shares of the company’s stock valued at $14,217,000 after buying an additional 304,065 shares during the last quarter. Finally, Gilder Gagnon Howe & Co. LLC raised its holdings in shares of Evolus by 287.2% in the fourth quarter. Gilder Gagnon Howe & Co. LLC now owns 702,239 shares of the company’s stock valued at $7,753,000 after buying an additional 520,859 shares during the last quarter. 90.69% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Evolus news, CFO Sandra Beaver sold 8,996 shares of the company’s stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total value of $119,286.96. Following the sale, the chief financial officer now owns 173,583 shares of the company’s stock, valued at $2,301,710.58. This represents a 4.93% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider David Moatazedi sold 6,251 shares of the company’s stock in a transaction dated Thursday, March 27th. The shares were sold at an average price of $12.40, for a total transaction of $77,512.40. Following the completion of the sale, the insider now directly owns 508,619 shares in the company, valued at $6,306,875.60. This trade represents a 1.21% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 60,575 shares of company stock worth $794,369. 5.90% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on EOLS shares. Barclays upped their target price on shares of Evolus from $22.00 to $25.00 and gave the company an “overweight” rating in a report on Wednesday, March 5th. Needham & Company LLC reiterated a “buy” rating and set a $22.00 price target on shares of Evolus in a research note on Thursday. HC Wainwright reiterated a “buy” rating and set a $27.00 price target on shares of Evolus in a research note on Thursday, April 10th. Finally, BTIG Research assumed coverage on shares of Evolus in a research note on Thursday, April 17th. They set a “buy” rating and a $21.00 price target on the stock. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $23.75.

Evolus Trading Down 2.9%

Shares of EOLS opened at $9.80 on Monday. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58. The firm’s 50-day moving average is $11.66 and its two-hundred day moving average is $12.54. Evolus, Inc. has a twelve month low of $8.67 and a twelve month high of $17.82. The firm has a market capitalization of $631.82 million, a P/E ratio of -10.77 and a beta of 1.11.

Evolus Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.